Aridis Pharmaceuticals (ARDS)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Oct 14, 2024 03:49 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Aridis Pharmaceuticals falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 3 | 2 | 1 | 1 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 3 | 2 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 33 | 44 | 23 | 30 |
Income After Depreciation & Amortization | 0 | -30 | -43 | -22 | -29 |
Non-Operating Income | NA | 0 | 1 | 0 | -1 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -30 | -42 | -22 | -30 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -30 | -42 | -22 | -30 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -30 | -42 | -22 | -30 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -30 | -42 | -22 | -29 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -30 | -43 | -22 | -29 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 18.78 | 12.29 | 9.17 | 8.46 |
Diluted EPS Before Non-Recurring Items | NA | -1.62 | -3.85 | -2.44 | -3.51 |
Diluted Net EPS (GAAP) | NA | -1.62 | -3.77 | -2.44 | -3.51 |
Fiscal Year end for Aridis Pharmaceuticals falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | 0.42 |
Cost Of Goods | NA | NA | NA | NA | 0.00 |
Gross Profit | NA | NA | NA | NA | 0.42 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 1.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -0.87 |
Non-Operating Income | NA | NA | NA | NA | 0.79 |
Interest Expense | NA | NA | NA | NA | 0.00 |
Pretax Income | NA | NA | NA | NA | -0.08 |
Income Taxes | NA | NA | NA | NA | 0.00 |
Minority Interest | NA | NA | NA | NA | 0.00 |
Investment Gains/Losses | NA | NA | NA | NA | 0.00 |
Other Income/Charges | NA | NA | NA | NA | 0.00 |
Income From Cont. Operations | NA | NA | NA | NA | -0.08 |
Extras & Discontinued Operations | NA | NA | NA | NA | 0.00 |
Net Income (GAAP) | NA | NA | NA | NA | -0.08 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | 37.43 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | -0.02 |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | 0.00 |